Partners’ Hub

APACCCEEC is a government institution under the Ministry of Agriculture and Food of the Republic of Bulgaria, established based on a Memorandum signed in 2014 in Bucharest. APACCCEEC coordinates initiatives and practical cooperation projects in agriculture between China and the Central and Eastern European countries.The Association functions as a platform to promote bilateral and multilateral business contacts between companies, organisations and associations from China and Central and Eastern Europe.Among the projects and activities developed by APACCCEEC are permanent pavilions, demonstration zones, participations in exhibitions and trade fairs, the organization of forums and events connecting the business and academia from both sides. In 2025, APACCCEEC inaugurated a new Permanent Pavilion in Ningbo, China, showcasing foods, beverages and cosmetics from the Central and Eastern European countries.

Empowering Innovation and Sustainability in the EU Agri-Food SectorThe Agri-Food Sector Group (SG Agri-Food) champions innovation, sustainability, and resilience throughout the food industry—from production to consumption. Operating within the Single Market and beyond, it facilitates connections between EU Agri-Food SMEs and essential partners, funding opportunities, and cutting-edge expertise. Additionally, the group acts as a voice for SMEs, communicating their needs to policymakers to shape effective and forward-thinking food sector policies.Our MissionBusiness, innovation, and sustainability are the core principles driving the Agri-Food Sector Group. The group actively supports solutions for a more sustainable European food system, promoting circular economy practices and shorter supply chains to build a more responsible and resilient future.SMEs are empowered to navigate the Single Market, explore international opportunities, and adapt to ever-evolving market demands. The group provides expertise in areas such as digitalization and advanced technologies, helping businesses thrive and maintain competitiveness. Support is also extended in accessing funding and resources to fuel growth and innovation.

The International Association of Science Parks and Areas of Innovation (IASP) is the leading association of innovation communities. A worldwide membership-based association founded in 1984. An independent, non-profit, non-governmental organisation.Managed by experts in science and technology parks and areas of innovation.A Board of Directors made up of members from many different countries.Procedures that ensure we will always retain a true international identity: there cannot be more than two voting directors from the same country.A multilingual management team with world headquarters in Malaga (Spain) and a branch office in Beijing (China).Our mission is to be the global network for science and technology parks (STPs), innovation districts (IDs), areas of innovation (AOIs) and other innovation spaces, driving growth, internationalisation and effectiveness for our members.

Genopole, founded in 1998, is the oldest French biocluster fully dedicated to biotechnology, genomics, cell and gene therapies as applied to healthcare, synthetic biology, bioproduction for food & agriculture, cosmetics and industry. It unites innovative high-tech life science companies, hospital, public and private research and higher education facilities in a single site in the south of Paris. Today, Genopole is a major actor in France’s research and a key element of its industrial landscape for biotech and genomics.Our three main strategic areas are innovative therapeutics, computational genomics and bioeconomy. Genopole has a mature and fertile campus with over 2,600 staff members employed onsite by 63 biotech companies, 21 public research labs, and 29 cutting-edge shared- access technology platforms and university training courses (University of Evry Paris-Saclay).Genopole is renowned for its scientific excellence in biotherapies. It is home to two French pioneers in the sector: Genethon for gene therapies in rare diseases, and I-Stem for the study of human pluripotent stem cells and their use in cell therapies. Indeed, Zolgensma, the first gene therapy to be approved for the childhood neuromuscular disease spinal muscular atrophy, was the fruit of research done at Genethon. The model developed by Genopole, that is, a biocluster uniting research, entrepreneurship, training and medicine, has shown its potential. An industrial biotherapies sector has come to be at Évry-Courcouronnes in partnership with national, European and global networks. Today, the value chain is complete, from R&D through to GMP production: initial and continuous training, academic research, technology transfer accelerator for rare and common diseases, businesses providing R&D and services, a stem cell bank under construction and a gene therapy production facility. The initial successes in clinical trials and the market arrival of the resulting therapeutic innovations for both rare and common diseases have laid a path for no less than a third revolution in medicine. Genopole and its actors are able and willing to accompany this revolution and bring answers to the challenges within it. They are helping to build a sector of biotherapies.